# BPC-157 TB-500: The Wolverine Blend, Read From the Research > BPC-157 TB-500 is the Wolverine blend — two distinct repair peptides pairing a cytoprotective, pro-angiogenic signal with an actin-binding cell-migration signal. A cited digest of what the animal literature shows and what is still unproven. BPC-157 supplies a cytoprotective, pro-angiogenic signal; TB-500 supplies an actin-binding cell-migration signal. This is a cited digest of what each constituent's literature establishes, and where the combined human data still reads blank. ## What the Wolverine blend is BPC-157 TB-500 is the two-peptide pairing the research community calls the Wolverine blend — a tissue-repair stack, not a single chemical entity and not an approved product. It pairs two synthetic peptides with separate sequences, sizes, and mechanisms. BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence `GEPPPGKPADDAGLV`, molecular weight ~1419.53 Da, derived from a protein found in human gastric juice [1]. TB-500 is a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ`, ~889.02 Da, corresponding to the actin-binding region (residues 17-23) of the 43-residue protein Thymosin Beta-4 [3]. The blend has no single molecular weight, no CAS number, and no standardized composition. Commercial research vials commonly pair the two at a fixed combined mass — a `10 mg + 10 mg` label is typical — but no peer-reviewed study has validated that ratio or any other. The values that are real are per-constituent, and they are the values this site tracks. One caveat sits over the whole blend from the start. Most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer fragment sold under the name [4][9]. That gap is inherited by the blend, and it is flagged on every page where the TB-500 channel carries weight. ## BPC-157 and TB-500: the two peptides in the Wolverine blend BPC-157 and TB-500 are two independent signals routed at one target. BPC-157 is the cytoprotective and pro-angiogenic channel: it up-regulates VEGFR2 and drives downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and accelerating blood-flow recovery in ischemic tissue [2]. TB-500 is the cytoskeletal channel: the `LKKTETQ` motif binds monomeric G-actin in a 1:1 complex, regulating the actin dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3][4]. #### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-derived pentadecapeptide acting as a cytoprotective and angiogenic signal; TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting as a cytoskeletal-migration signal. Different sequences, different sizes (~1419 Da vs ~889 Da), and different mechanisms — they share only the broad goal of supporting repair [3][4]. #### What is the difference between BPC-157 and TB-500? (mechanism view) Functionally, BPC-157 acts locally on the vasculature and on fibroblasts, while TB-500 acts intracellularly on the actin cytoskeleton across migrating cells. The structural basis is well characterized for each: VEGFR2 up-regulation for BPC-157 [2], and 1:1 G-actin sequestration via dual-end capping for the parent Thymosin Beta-4 [3]. ## Why the BPC-157 TB-500 stack is combined The rationale for the BPC-157 + TB-500 stack is complementary mechanisms: a local angiogenic and cytoprotective signal from BPC-157 paired with a cytoskeletal cell-migration signal from TB-500, described as acting through largely non-overlapping pathways. That is the entire basis of the "synergy" claim. #### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms: BPC-157's angiogenic and cytoprotective signal plus TB-500's cytoskeletal-migration signal. This is a theoretical extrapolation from each peptide's independently characterized mechanism, not a finding from a controlled combination study. No peer-reviewed work defines a synergy ratio, dose, or endpoint for the two given together. That distinction is the spine of this site. The combination is plausible on paper; it is unproven in fact. Every blend-level claim here carries that status explicitly. For the studies that do exist — all on the individual peptides, almost all in animals — see the [BPC-157 TB-500 research findings](/research) and [the animal tendon and ligament studies](/tendon-repair). ## What the blend is studied for #### What is the Wolverine peptide blend? It is a research-community name for the BPC-157 + TB-500 pairing, discussed as a tissue-repair stack. It is not a single molecule and not an approved product, and the name borrows nothing from its pop-culture sense — the subject is the peptide blend [1][3]. #### What is BPC-157 and TB-500? BPC-157 is a 15-amino-acid pentadecapeptide from a human gastric-juice protein; TB-500 is the synthetic `Ac-LKKTETQ` fragment of Thymosin Beta-4. The blend pairs them as a tissue-repair stack with two distinct mechanisms [1][3]. In animal models the constituents have been studied for tendon and ligament repair [1][6], tendon-to-bone and muscle-to-bone healing [7][13], and angiogenesis and wound healing [2][4]. Human efficacy data for the combination do not exist. For the regulatory picture — neither peptide is FDA-approved, both are WADA-prohibited — see [FDA and WADA status of BPC-157 and TB-500](/legal-status). --- A two-channel research console: the BPC-157 and TB-500 literature logged to source, with the blend's missing human readouts left blank rather than filled in — not a clinic, not a vendor, not a prescription.